Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 170

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 170
---
 2022, the Company executed a promissory note in favor of Vivus with a principal amount of $10,201,758 in connection with the Vivus Settlement Agreement. For more information, see the section above titled “-Vivus Settlement Agreement, Promissory Note and the Security Agreement.” Cash Flows The following table summarizes our cash flows for the years ended December 31, 2023, and 2022:

|                                                     | ​ |                     |            | ​ |      |             | ​ |
| ​                                                   | ​ | For the Years Ended |            |   |      |             | ​ |
| ​                                                   | ​ |        December 31, |            |   |      |             | ​ |
|                                                     |   |                2023 |            |   | 2022 |             |   |
| Net cash used in operating activities               | ​ |                   $ | -7,626,529 | ​ |    $ | -12,797,325 | ​ |
| Net cash provided by/(used in) financing activities | ​ |                   ​ | 11,537,240 | ​ |    ​ |  -1,623,983 | ​ |
| Net increase (decrease) in cash                     | ​ |                   $ |  3,910,711 | ​ |    $ | -14,421,308 | ​ |

Cash Flows from Operating Activities Net cash used in operating activities for the year ended December 31, 2023, was $7,626,529, which primarily reflected our net loss of $8,163,188. Adjustments to reconcile net loss to net cash provided by operating activities of $88,255 consisting primarily of depreciation and amortization, change in the fair value of derivative and warrant liabilities, loss on the issuance of Series A Preferred Stock, stock-based compensation expense, noncash warrant expenses, and changes in operating assets and liabilities of $624,914. Net cash used in operating activities for the year ended December 31, 2022, was $12,797,325, which primarily reflected our net loss of $20,037,573. Adjustments to reconcile net loss to net cash provided by operating activities of $10,542,319 consisting primarily of depreciation and amortization, intangible asset impairment, gain on Vivus settlement, stock compensation and changes in operating assets and liabilities of $3,302,071. Cash Flows from Financing Activities Net cash provided by financing activities was $11,